Company intelligence / Profile preview
Intra-ImmuSG
Singapore, Singaporeintra-immusg.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
PRL3-zumab has completed a successful Phase II clinical trial with excellent drug safety profile and positive efficacy signals. It has shown potential for treating patients who are no longer suitable for immunotherapy or chemotherapy, with longer Progress Free Survival than prior treatments without drug-related toxicity[3].
- Therapeutic areas
- Oncology
- Modalities
- Humanized antibody drugsMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Intra-ImmuSG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intra-ImmuSG.